Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

E-Cigarette ‘Deeming’ Rule In OMB Review As Health Groups Urge Claim Enforcement

This article was originally published in The Tan Sheet

Executive Summary

FDA’s proposed final rule to deem e-cigarettes and other novel products, cigars and pipe tobacco subject to its tobacco oversight is under OMB review. The American Cancer Society and other medical groups, meanwhile, urge immediate action against e-cigarette marketers making smoking cessation claims.

You may also be interested in...



With Deeming Rule Pending, FDA Reminds E-Cigarette Firms About Drug Claims

In a proposed rule, FDA describes to a new audience its long-established policy on drugs and devices marketed for off-label indications. The agency says “some ambiguity surrounds the circumstances” that determine whether a product is regulated as tobacco or as a drug, device or combination product

Turning Back Calendar Could Keep E-Cigarettes Available Without Approval

Exercising enforcement discretion concerning the grandfather date for e-cigarettes and other products covered in FDA’s proposed deeming rule would not be the agency’s first use of the enforcement tool in implementing Tobacco Control Act regulations.

Illumina Will Pay $8Bn To Buy Back Cancer Screening Start-Up Grail

Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.

Topics

UsernamePublicRestriction

Register

LL016789

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel